NasdaqGS:ANABBiotechs
AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model
AnaptysBio (ANAB) has completed the spin off of First Tracks Biotherapeutics and now operates as a royalty focused company centered on collaborations with GSK and Vanda, alongside fresh leadership appointments.
See our latest analysis for AnaptysBio.
The latest spin off, leadership changes and focus on royalty income come after a powerful multi year run, with the share price up 40.5% year to date and 1 year total shareholder return above 7x. However, the 7 day share price return of 8.9% and...